Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 30 Dec 2025 for Cogent Biosciences, Inc., €2.7M.
Filing timeline
BuySaleJessica Sachs
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jessica Sachs: trading record in brief
Jessica Sachs (senior executive) discloses dealings in Cogent Biosciences, Inc. to SEC (Form 4). We count 6 filings; the first trade dates from 31 December 2021 and the latest from 26 December 2025.
Every open-market trade on record is a sale: 1 sale worth €2.7M. Other entries cover 5 share grants. So far in 2025, the count stands at no purchases and 1 sale.
On 30 December 2025 came the latest disclosure, an open-market sale for €2.7M in Cogent Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jessica Sachs
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
82,642 shares@ US$38.7099.7% of flowCommon StockSEC:0001193125-25-337050:0
50,000 shares0Common StockSEC:0001193125-25-326773:0
622 shares@ US$7.3950.0001% mcap35.1% of flowCommon StockSEC:0000899243-22-024711:0
674 shares@ US$6.8170.1% of flowCommon StockSEC:0000899243-22-000694:0
4 of 4 declarations
